199 related articles for article (PubMed ID: 30357650)
1. Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients.
Zhou D; Li J; Bui K; Learoyd M; Berges A; Milenkova T; Al-Huniti N; Tomkinson H; Xu H
Clin Pharmacokinet; 2019 May; 58(5):615-625. PubMed ID: 30357650
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological issues concerning olaparib capsule and tablet formulations in treating ovarian cancer: Are they really the same drug?
Perego G; Nozza R; Oggionni E; Cabiddu M; Scolari C; Omati E; Castelli EA; Petrelli F
J Oncol Pharm Pract; 2020 Jun; 26(4):967-971. PubMed ID: 32041467
[TBL] [Abstract][Full Text] [Related]
3. Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations.
Moore KN; Birrer MJ
Oncologist; 2018 Jun; 23(6):697-703. PubMed ID: 29593098
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
van der Noll R; Jager A; Ang JE; Marchetti S; Mergui-Roelvink MWJ; de Bono JS; Lolkema MP; de Jonge MJA; van der Biessen DA; Brunetto AT; Arkenau HT; Tchakov I; Beijnen JH; De Grève J; Schellens JHM
Invest New Drugs; 2020 Aug; 38(4):1096-1107. PubMed ID: 31637669
[TBL] [Abstract][Full Text] [Related]
5. Olaparib Tablet: A Review in Ovarian Cancer Maintenance Therapy.
Heo YA; Dhillon S
Target Oncol; 2018 Dec; 13(6):801-808. PubMed ID: 30456461
[TBL] [Abstract][Full Text] [Related]
6. Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.
Dirix L; Swaisland H; Verheul HM; Rottey S; Leunen K; Jerusalem G; Rolfo C; Nielsen D; Molife LR; Kristeleit R; Vos-Geelen J; Mau-Sørensen M; Soetekouw P; van Herpen C; Fielding A; So K; Bannister W; Plummer R
Clin Ther; 2016 Oct; 38(10):2286-2299. PubMed ID: 27745744
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients.
Zhou D; Li J; Learoyd M; Bui K; Berges A; Milenkova T; Al-Huniti N; Tomkinson H; Xu H
Clin Pharmacol Ther; 2019 Jun; 105(6):1492-1500. PubMed ID: 30585620
[TBL] [Abstract][Full Text] [Related]
8. Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors.
Rolfo C; Swaisland H; Leunen K; Rutten A; Soetekouw P; Slater S; Verheul HM; Fielding A; So K; Bannister W; Dean E
Adv Ther; 2015 Jun; 32(6):510-22. PubMed ID: 26048134
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours.
Yuan P; Shentu J; Xu J; Burke W; Hsu K; Learoyd M; Zhu M; Xu B
Cancer Chemother Pharmacol; 2019 May; 83(5):963-974. PubMed ID: 30887180
[TBL] [Abstract][Full Text] [Related]
10. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
Plummer R; Swaisland H; Leunen K; van Herpen CM; Jerusalem G; De Grève J; Lolkema MP; Soetekouw P; Mau-Sørensen M; Nielsen D; Spicer J; Fielding A; So K; Bannister W; Molife LR
Cancer Chemother Pharmacol; 2015 Oct; 76(4):723-9. PubMed ID: 26242220
[TBL] [Abstract][Full Text] [Related]
11. An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.
Mateo J; Moreno V; Gupta A; Kaye SB; Dean E; Middleton MR; Friedlander M; Gourley C; Plummer R; Rustin G; Sessa C; Leunen K; Ledermann J; Swaisland H; Fielding A; Bannister W; Nicum S; Molife LR
Target Oncol; 2016 Jun; 11(3):401-15. PubMed ID: 27169564
[TBL] [Abstract][Full Text] [Related]
12. Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet formulation of olaparib.
Friedlander M; Shannon C; Goh J; Scott C; Mileshkin L
Asia Pac J Clin Oncol; 2018 Dec; 14(6):459-464. PubMed ID: 30479036
[TBL] [Abstract][Full Text] [Related]
13. A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer.
Geenen JJJ; Dackus GMHE; Schouten PC; Pluim D; Marchetti S; Sonke GS; Jóźwiak K; Huitema ADR; Beijnen JH; Schellens JHM; Linn SC
Int J Cancer; 2021 Jun; 148(12):3041-3050. PubMed ID: 33539540
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1).
van der Noll R; Jager A; Ang JE; Marchetti S; Mergui-Roelvink MWJ; Lolkema MP; de Jonge MJA; van der Biessen DA; Brunetto AT; Arkenau HT; Tchakov I; Beijnen JH; de Bono JS; Schellens JHM
Invest New Drugs; 2020 Aug; 38(4):1117-1128. PubMed ID: 31667659
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours.
Yonemori K; Tamura K; Kodaira M; Fujikawa K; Sagawa T; Esaki T; Shirakawa T; Hirai F; Yokoi Y; Kawata T; Hatano B; Takahashi Y
Cancer Chemother Pharmacol; 2016 Sep; 78(3):525-31. PubMed ID: 27422301
[TBL] [Abstract][Full Text] [Related]
16. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.
Rolfo C; de Vos-Geelen J; Isambert N; Molife LR; Schellens JHM; De Grève J; Dirix L; Grundtvig-Sørensen P; Jerusalem G; Leunen K; Mau-Sørensen M; Plummer R; Learoyd M; Bannister W; Fielding A; Ravaud A
Clin Pharmacokinet; 2019 Sep; 58(9):1165-1174. PubMed ID: 30877569
[TBL] [Abstract][Full Text] [Related]
18. Olaparib: A tale of two dosage forms.
Christ TN
Semin Oncol; 2019 Feb; 46(1):100-101. PubMed ID: 30583807
[TBL] [Abstract][Full Text] [Related]
19. Olaparib: first global approval.
Deeks ED
Drugs; 2015 Feb; 75(2):231-40. PubMed ID: 25616434
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer.
Yu Y; Durairaj C; Shi H; Wang DD
J Clin Pharmacol; 2020 Feb; 60(2):218-228. PubMed ID: 31489639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]